Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: Findings of the third national survey on use of psychotropic medications in China

Australian and New Zealand Journal of Psychiatry

Volumn 49, Issue 2, 2015, Pages 129-136

  Li, Qian ^a   Xiang, Yu Tao ^b   Su, Yun Ai ^a   Shu, Liang ^a   Yu, Xin ^a   Chiu, Helen F K ^c   Correll, Christoph U ^d   Ungvari, Gabor S ^e   Lai, Kelly Y C ^c   Ma, Cui ^f   Wang, Gao Hua ^g   Bai, Pei Shen ^h   Li, Tao ⁱ   Sun, Li Zhong ^j   Shi, Jian Guo ^k   Chen, Xian Sheng ^l   Mei, Qi Yi ^m   Li, Ke Qing ⁿ   Si, Tian Mei ^a  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^b University of Macau   (Macao)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d ZUCKER HILLSIDE HOSPITAL   (United States)

^e UNIVERSITY OF NOTRE DAME   (Australia)

^f Guangzhou Psychiatric Hospital   (China)

^g WUHAN UNIVERSITY   (China)

^h SHANXI MEDICAL UNIVERSITY   (China)

ⁱ SICHUAN UNIVERSITY   (China)

^j Neuropsychiatric Hospital   (China)

^k Xi'an Mental Health Center   (China)

^l Jiangxi Cancer Hospital   (China)

^m Suzhou Guangji Hospital   (China)

ⁿ Hebei Mental Health Center   (China)

more..

Author keywords

Antipsychotic polypharmacy; prescription patterns; schizophrenia

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE;

ADULT; CHINA; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ONSET AGE; PATIENT SATISFACTION; POLYPHARMACY; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; MIDDLE AGED; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIPSYCHOTIC AGENTS; CHINA; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; POLYPHARMACY; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 84921350985     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867414536931     Document Type: Review

References (49)

1. Practice Guideline for the Treatment of Patients with Schizophrenia. Washington, DC: American Psychiatric Press ; 1997 :
2. Austin SF, Mors O, Secher RG, et al. Predictors of recovery in first episode psychosis: The OPUS cohort at 10 year follow-up. Schizophrenia Research. 2013 ; 150: 163-168
3. Barbui C, Signoretti A, Mule S, et al. Does the addition of a second antipsychotic drug improve clozapine treatment?. Schizophrenia Bulletin. 2009 ; 35: 458-468
4. Carnahan RM, Lund BC, Perry PJ, et al. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatrica Scandinavica. 2006 ; 113: 135-141
5. Chong MY, Tan CH, Fujii S, et al. Antipsychotic drug prescription for schizophrenia in East Asia: Rationale for change. Psychiatry and Clinical Neurosciences. 2004 ; 58: 61-67
6. Chong SA, Sachdev P, Mahendran R, et al. Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state psychiatric hospital in Singapore. Australian and New Zealand Journal of Psychiatry. 2000 ; 34: 988-991
7. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database of Systematic Reviews. 2009 ; ( 3 ):
8. Correll CU, Gallego JA. Antipsychotic polypharmacy: A comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatric Clinics of North America. 2012 ; 35: 661-681
9. Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophrenia Research. 2007 ; 89: 91-100
10. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophrenia Bulletin. 2009 ; 35: 443-457
11. Elie D, Poirier M, Chianetta J, et al. Cognitive effects of antipsychotic dosage and polypharmacy: A study with the BACS in patients with schizophrenia and schizoaffective disorder. Journal of Psychopharmacology. 2010 ; 24: 1037-1044
12. Essock SM, Schooler NR, Stroup TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. American Journal of Psychiatry. 2011 ; 168: 702-708
13. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005 ; 5: 26
14. Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophrenia Research. 2012a ; 138: 18-28
15. Gallego JA, Nielsen J, De Hert M, et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opinion on Drug Safety. 2012b ; 11: 527-542
16. Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. Journal of Clinical Psychiatry. 2004 ; 65: 1377-1388
17. Goff DC, Dixon L. Antipsychotic polypharmacy: Are two ever better than one?. American Journal of Psychiatry. 2011 ; 168: 667-669
18. Guy W ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare ; 1976 :
19. Jenkinson C, Layte R. Development and testing of the UK SF-12 (short form health survey). Journal of Health Services Research and Policy. 1997 ; 2: 14-18
20. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena ; 1998 Italy ; 1998. 55.
21. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet. 2013 ; 382: 951-962
22. Liang H, Xue Y, Byrd TA, et al. Electronic data interchange usage in China's healthcare organizations: The case of Beijing's hospitals. International Journal of Information Management. 2004 ; 24: 507-522
23. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. American Journal of Psychiatry. 1994 ; 151: 1744-1752
24. Millier A, Sarlon E, Azorin JM, et al. Relapse according to antipsychotic treatment in schizophrenic patients: A propensity-adjusted analysis. BMC Psychiatry. 2011 ; 11: 24
25. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry. 2010 ; 67: 26-36
26. Morrato EH, Dodd S, Oderda G, et al. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: Experience in a multistate Medicaid population, 1998-2003. Clinical Therapeutics. 2007 ; 29: 183-195
27. TESS (Treatment Emergent Symptom Scale-Write-in). Psychopharmacology Bulletin. 1985 ; 21: 1069-1072
28. Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: Results from a Danish Register Study. Journal of Clinical Psychopharmacology. 2012 ; 32: 678-683
29. Paillere-Martinot M, Caclin A, Artiges E, et al. Cerebral gray and white matter reductions and clinical correlates in patients with early onset schizophrenia. Schizophrenia Research. 2001 ; 50: 19-26
30. Roh D, Chang JG, Kim CH, et al. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: A 5-year comparison. Australian and New Zealand Journal of Psychiatry. 2014 ; 48: 52-60
31. Si TM, Shu L, Yu X, et al. Antipsychotic drug patterns of schizophrenia in China: A cross-sectional study [in Chinese]. Chinese Journal of Psychiatry. 2004 ; 37: 152-155
32. Sim K, Su A, Chan YH, et al. Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore. Psychiatry and Clinical Neurosciences. 2004a ; 58: 324-329
33. Sim K, Su A, Fujii S, et al. Antipsychotic polypharmacy in patients with schizophrenia: A multicentre comparative study in East Asia. British Journal of Clinical Pharmacology. 2004b ; 58: 178-183
34. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: Update to the algorithms for treatment of bipolar I disorder. Journal of Clinical Psychiatry. 2005 ; 66: 870-886
35. Tani H, Uchida H, Suzuki T, et al. Interventions to reduce antipsychotic polypharmacy: A systematic review. Schizophrenia Research. 2013 ; 143: 215-220
36. Tapp AM, Wood AE, Kilzieh N, et al. Antipsychotic polypharmacy: Do benefits justify the risks?. Annals of Pharmacotherapy. 2005 ; 39: 1759-1760
37. Taylor D, Paton C, Kerwin R The Maudsley Prescribing Guidelines. London: Martin Dunitz ; 2003 :
38. Tiihonen J, Suokas JT, Suvisaari JM, et al. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Archives of General Psychiatry. 2012 ; 69: 476-483
39. Tor PC, Ng TP, Yong KH, et al. Adjunctive benzodiazepine treatment of hospitalized schizophrenia patients in Asia from 2001 to 2008. International Journal of Neuropsychopharmacology. 2011 ; 14: 735-745
40. Voruganti L, Heslegrave R, Awad AG, et al. Quality of life measurement in schizophrenia: Reconciling the quest for subjectivity with the question of reliability. Psychological Medicine. 1998 ; 28: 165-172
41. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry. 2003 ; 64: 663-667
42. Xiang YT, Li Y, Correll CU, et al. Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001-2009). International Journal of Geriatric Psychiatry. 2014 ; 29: 359-366
43. Xiang YT, Ma X, Cai ZJ, et al. Prevalence and socio-demographic correlates of schizophrenia in Beijing, China. Schizophrenia Research. 2008 ; 102: 270-277
44. Xiang YT, Wang CY, Si TM, et al. Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009). Pharmacopsychiatry. 2012 ; 45: 7-12
45. Xiang YT, Weng YZ, Leung CM, et al. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry. 2007a ; 40: 47-52
46. Xiang YT, Weng YZ, Leung CM, et al. Clinical and social determinants of long-term use of benzodiazepines and its impact on quality of life of Chinese schizophrenia patients. Pharmacopsychiatry. 2007b ; 40: 269-274
47. Zhang S, Tian J, Liu QL, et al. Reliability and validity of SF-12 among floating population [in Chinese]. Chinese Journal of Public Health. 2011 ; 27: 226-227
48. Zhang YS, Si TM, Li KQ. A survey of antipsychotic combination therapy and its related factors in China in 2006 [in Chinese]. Chinese Journal of Psychiatry. 2012 ; 45: 207-212
49. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Current Opinion in Psychiatry. 2010 ; 23: 103-111